News

New Research Reveals 10x Higher Babesiosis Cases Than CDC Reports

New Research Reveals 10x Higher Babesiosis Cases Than CDC Reports

Significant Increase in Babesiosis Cases Revealed

Recent studies conducted by 60 Degrees Pharmaceuticals indicate that the number of adults in the U.S. who file for medical reimbursement due to babesiosis is vastly underestimated. The research, performed by Komodo Health, highlights that approximately 25,000 adults in the United States make these claims every year, compared to the Centers for Disease Control and Prevention’s (CDC) estimates which suggest only 2,000 cases annually.

Understanding Persistent Symptoms Linked to Babesiosis

These alarming statistics raise important questions regarding the persistence of symptoms related to babesiosis. Data show that a notable 45 percent of individuals with long-standing babesiosis cases report experiencing chronic fatigue. This correlation suggests that healthcare providers should consider diagnosing babesiosis in patients who present with unexplained chronic fatigue.

Implications for Healthcare Providers

In light of the new data, doctors treating patients with chronic fatigue might want to investigate the possibility of babesiosis as a contributing factor. Chronic fatigue is often the last symptom to resolve in cases of acute babesiosis and can persist long after the initial infection has been treated. Many doctors believe that the true duration of infection could indeed last much longer than previously thought.

New Initiatives and Drug Development

60 Degrees Pharmaceuticals is working diligently to address this public health concern. The company has launched two clinical trials specifically focused on the treatment of babesiosis and anticipates initiating a third trial soon. Findings from these studies will ultimately inform their New Drug Application (NDA) submission to the FDA projected for the upcoming year.

Clinical Trials for Babesiosis Treatment

The ongoing clinical trials sponsored by 60 Degrees Pharmaceuticals include studies to evaluate the safety and efficacy of tafenoquine, a drug previously approved for malaria prophylaxis. The results of these trials are not only crucial for understanding the treatment landscape of babesiosis but are also expected to yield significant insights regarding the long-term effects of the disease.

Broader Context of Babesiosis in the U.S.

The data collection methods used in the claims analysis capture around 40 percent of U.S. diagnostic data and reveal that over 12 million adults experienced chronic fatigue lasting six months or more within a three-year span. Despite this disturbing trend, guidelines from the Infectious Diseases Society of America currently do not require healthcare professionals to include babesiosis on the list of differential diagnoses for patients reporting chronic fatigue.

Potential for New Insights on Disease Incidence

The company’s mission extends beyond immediate treatment options. A molecular incidence study commissioned by 60 Degrees Pharmaceuticals aims to deepen understanding of the connection between persistent fatigue and babesiosis, potentially establishing a clearer picture of the actual incidence of the disease. Once published, the findings could significantly influence future research and awareness.

What You Should Know About ARAKODA®

ARAKODA® (tafenoquine), developed by the Walter Reed Army Institute of Research, is an established medication that received FDA approval for malaria prevention in 2018. Available in the U.S. and Australia, it is particularly noted for its long half-life, making it a convenient option compared to traditional malaria prophylactic medications. Patients at risk of malaria typically take ARAKODA as directed before and during their travels in endemic regions.

Safety Information Regarding ARAKODA®

As with any medication, ARAKODA comes with important safety considerations. It is contraindicated in patients with G6PD deficiency and can cause severe adverse reactions. These risks underscore the need for proper medical evaluation before prescription. Potential side effects include headaches, anxiety, and gastrointestinal disturbances, necessitating monitoring for any severe reactions during treatment.

About 60 Degrees Pharmaceuticals

Founded in 2010, 60 Degrees Pharmaceuticals, Inc. is dedicated to developing cutting-edge treatments for infectious diseases. Their collaboration with reputable research entities emphasizes a strong commitment to addressing the global health challenge posed by infectious diseases. The company is headquartered in Washington, D.C. and has a majority-owned subsidiary in Australia, continuing to innovate in the pharmaceutical space.

Frequently Asked Questions

What is the main finding of the new study on babesiosis?

The study revealed that approximately 25,000 U.S. adults seek medical reimbursement for babesiosis-related costs each year, significantly more than CDC estimates.

How does chronic fatigue relate to babesiosis?

Many patients with persistent babesiosis report chronic fatigue, with a significant percentage experiencing symptoms for longer than six months.

What is 60 Degrees Pharmaceuticals currently working on?

The company is conducting several clinical trials to evaluate treatments for babesiosis and plans to submit a New Drug Application to the FDA.

What is tafenoquine, and how is it used?

Tafenoquine, marketed as ARAKODA®, is an antimalarial drug that is also being studied for its efficacy in treating babesiosis.

What should patients know about ARAKODA®?

Patients should be aware of the potential risks associated with ARAKODA® and consult healthcare providers to ensure safe use, especially regarding G6PD deficiency.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 33

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 221

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 100

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 137

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 207

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 92

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 90

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Products Secures $140 Million in NASA Liquid Hydrogen Contracts

Updated Category News Views 85

Air Products Receives Significant NASA Contracts Air Products, a leading supplier in the industrial gases market, recently announced an impressive contract award from NASA valued at over $140 million. This contract aims at supplying liquid hydrogen for various NASA facilities, most notably the renowned Kennedy Space Center and other significant sites where vital space...

Continue Reading
Navigating Market Realities: A Look Ahead for Investors

Updated Category News Views 158

The Uncomfortable Truth About Market Valuations Many investors may feel uneasy hearing this, but it’s essential to face the real data regarding market potential. After analyzing the last 40 years of market information from various developed economies, including movements in China, the reality might deter those banking on robust returns in the forthcoming decade. There's...

Continue Reading
Sodexo Unveils Its Universal Registration Document for 2025

Updated Category News Views 367

Introduction to Sodexo's Fiscal 2025 Document Sodexo has made significant strides in enhancing transparency and providing essential information through its recently filed Fiscal 2025 Universal Registration Document (URD). This document, which is now accessible to investors and stakeholders, showcases the company's ongoing commitment to accountability and sustainability....

Continue Reading
Paratus Energy's Q4 2025 Results: Key Indicators to Analyze

Updated Category News Views 197

Paratus Energy Services Ltd. (PLSV) is about to drop its unaudited interim Q4 2025 financial results on February 27, 2026. But here’s the kicker—traders are left with scant intel leading into this call, and that can rattle markets. First off, let’s talk about the earnings whispers. The usual playbook includes scouring through EPS projections and revenue figures, but...

Continue Reading
Keefe Adjusts Rating for Bank of N.T. Butterfield Amid Challenges

Updated Category News Views 72

Keefe Downgrades the Bank of N.T. Butterfield Stock Rating Recently, Keefe, Bruyette & Woods revised its recommendation for Bank of N.T. Butterfield (NYSE: NTB) stock, shifting the rating from Outperform to Market Perform. The price target has also been adjusted from $44 to $41. This reflects the bank's forecast of significant net interest income (NII) challenges...

Continue Reading